GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gossamer Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.43−0.34 (-3.88%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Gossamer Bio, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Revenue from contracts with collaborators | $48.47M | $24.02M | $0 | $0 | 100.0% | +101.8% |
| Revenue from sale of licenses | $0 | $90.68M | $0 | $0 | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Gossamer Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.